6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates

6.5 Range of Application, Dosage, Mode of Administration 6.5.1 General Information 6.5.2 Indications for Replacement Therapy Using Factor Concentrates 6.5.3 Dosage, Mode of Administration 6.5.3.1 Replacement in Children with Hemophilia A, B or von Willebrand Syndrome 6.5.3.2 Replacement in Adults with Hemophilia A, B or von Willebrand Syndrome 6.5.3.3 Indications and Recommended Doses for Treating Patients with Factor VIII Inhibitors in Hemophilia A 6.5.4 Absolute and Relative Contraindications

[1]  K. Lechner.  Indikation und Anwendung von rekombinanten Gerinnungsfaktoren (Faktoren Vlla, VIII, IX) , 2011 .

[2]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[3]  C. Kannicht,et al.  VON WILLEBRAND FACTOR (VWF)-BINDING TO COLLAGEN III UNDER PHYSIOLOGICAL FLOW CONDITIONS AND VWF-MEDIATED PLATELET BINDING , 2007 .

[4]  J. G. van der Bom,et al.  Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. , 2007, Blood.

[5]  L. Mantovani,et al.  Current use of by‐passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  E. Berntorp,et al.  Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  J. Oldenburg,et al.  Genetic risk factors for inhibitors to factors VIII and IX , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  A. Batorova,et al.  Continuous infusion of coagulation factors: current opinion , 2006, Current opinion in hematology.

[9]  L. Mantovani,et al.  Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  P. Mannucci,et al.  Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  H. Beeser.  Characterization of highly purified factor VIII products , 1991, Annals of Hematology.

[12]  F. Rosendaal,et al.  Thirty years of hemophilia treatment in the Netherlands, 1972-2001. , 2004, Blood.

[13]  P. Giangrande,et al.  Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven®) in children vs. adults with haemophilia A , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  M. Carcao,et al.  Prophylactic factor replacement in hemophilia. , 2004, Blood reviews.

[15]  Roshni Kulkarni,et al.  Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. , 2004, Blood.

[16]  P. Mannucci,et al.  Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. , 2004, Blood.

[17]  B. Lindgren,et al.  On‐demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  R. Gruppo,et al.  Comparative effectiveness of full‐length and B‐domain deleted factor VIII for prophylaxis – a meta‐analysis , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  C. Kessler,et al.  The safety and efficacy of B‐domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A , 2003 .

[20]  A. Federici,et al.  Clinical efficacy of highly purified, doubly virus‐inactivated factor VIII/von Willebrand factor concentrate (Fanhdi®) in the treatment of von Willebrand disease: a retrospective clinical study , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  D. Grobbee,et al.  Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcome , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  K. Fischer,et al.  Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  P. Mannucci,et al.  Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. , 2002, Blood.

[24]  P. Giangrande,et al.  Quality‐of‐life differences between prophylactic and on‐demand factor replacement therapy in European haemophilia patients , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  Mannucci,et al.  Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  Mannucci,et al.  Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  M. Barthels.  Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors. , 1999, Thrombosis research.

[28]  L. Kingsley,et al.  Adenotonsillectomy in children with von Willebrand disease. , 1999, Archives of otolaryngology--head & neck surgery.

[29]  Shapiro,et al.  A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors , 1998 .

[30]  A D Shapiro,et al.  Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery , 1998, Thrombosis and Haemostasis.

[31]  C. Kessler,et al.  Haemophilia care within the United Kingdom , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[32]  C. Kessler,et al.  Guidelines on treatment of haemophilia in Sweden , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[33]  J. Sixma,et al.  Factor VIII and von Willebrand Factor , 1998, Thrombosis and Haemostasis.

[34]  P. Mannucci,et al.  A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[35]  K. Lechner.  Antikörperbildung - die derzeit gravierendste Komplikation der Substitutionstherapie bei Hämophilie , 1997 .

[36]  D. Ginsburg,et al.  Von Willebrand disease. , 2008, Pediatric clinics of North America.

[37]  K. Lechner,et al.  Spontane Faktor-VIII-Inhibitoren , 1996 .

[38]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[39]  E. Berntorp,et al.  Plasma product treatment in various types of von Willebrand's disease. , 1994, Haemostasis.

[40]  J. Lusher.  Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease. , 1994, Haemostasis.

[41]  Z. Ruggeri.  Pathogenesis and classification of von Willebrand disease. , 1994, Haemostasis.

[42]  K. Schimpf.  Therapie der Hämophilien , 1994 .

[43]  E. Berntorp.  Die Auswirkungen einer Substitutionstherapie auf das Immunsystem von Blutern , 1994 .

[44]  W. Schramm.  Konsensus-Empfehlungen zur Hämophiliebehandlung in Deutschland , 1994 .

[45]  I. Scharrer.  Rekombinante Faktor VIII-Konzentrate , 1994 .

[46]  S. Lethagen,et al.  Biochemical and In Vivo Properties of High Purity Factor IX Concentrates , 1993, Thrombosis and Haemostasis.

[47]  M. Hilgartner,et al.  Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII , 1993, The Lancet.

[48]  W. Schramm.  Experience with prophylaxis in Germany. , 1993, Seminars in hematology.

[49]  J. Vermylen,et al.  A Higher than Expected Incidence of Factor VIII Inhibitors in Multitransfused Haemophilia A Patients Treated with an Intermediate Purity Pasteurized Factor VIII Concentrate , 1993, Thrombosis and Haemostasis.

[50]  M. A. Lamb,et al.  Viral safety of clotting factor concentrates. , 1993, Seminars in thrombosis and hemostasis.

[51]  A. Thompson.  Factor IX concentrates for clinical use. , 1993, Seminars in thrombosis and hemostasis.

[52]  J. Gill,et al.  Therapy of Factor VIII Deficiency , 1993, Seminars in thrombosis and hemostasis.

[53]  J. Oldenburg,et al.  Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. , 1992, Haemostasis.

[54]  P. Mannucci,et al.  Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. , 1992, Blood.

[55]  E. Sacchi,et al.  Intravenous and Subcutaneous Administration of Desmopresssin (DDAVP) to Hemophiliacs: Pharmacokinetics and Factor VIII Responses , 1987, Thrombosis and Haemostasis.

[56]  H. V. van Houwelingen,et al.  The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. , 1981, The New England journal of medicine.

[57]  D. Price,et al.  A randomized study of factor VIII or prothrombin complex concentrate infusions in children with haemophilia and antibodies to factor VIII. , 1979, Australian and New Zealand journal of medicine.

[58]  K. Schimpf,et al.  Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study. , 2009, Scandinavian journal of haematology. Supplementum.

[59]  C. Abildgaard,et al.  Treatment of hemophilia with glycine-precipitated factor 8. , 1966, The New England journal of medicine.